Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients
- Conditions
- Cancer patients with brain metastasisTherapeutic area: Not possible to specify
- Registration Number
- CTIS2024-513997-23-00
- Lead Sponsor
- niversitair Ziekenhuis Brussel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Patients who have given informed consent, Age 18 years or older patients with brain metastasized cancer, with at least 1 brain lesion of at least 8 mm maximal diameter, as measured by CT or MRI, Patients with potentially HER2-positive cancer. Either a HER2 staining should have been done in standard of care, or sufficient tissue should be available for HER2-staining for study purpose
Pregnant patients, Breast feeding patients, Patients with recent (< 1 week) gastrointestinal disorders with diarrhea as major symptom, Patients with any serious active infection, Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the test radiopharmaceutical, Patients who cannot communicate reliably with the investigator, Patients at increased risk of death from a pre-existing concurrent illness
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method